Related Experiment Videos
Multilobated non-Hodgkin's lymphoma. A clinicopathologic entity.
J van Baarlen1, H J Schuurman, J A van Unnik
1Institute for Pathology, University Hospital, Utrecht, The Netherlands.
Cancer
|April 1, 1988
Summary
Multilobated non-Hodgkin's lymphoma (NHL) is a distinct variant characterized by specific cell morphology. This research highlights its unique presentation, treatment response, and suggests it represents a separate disease entity.
Area of Science:
- Hematopathology
- Oncology
- Immunology
Background:
- Multilobated non-Hodgkin's lymphoma (NHL) is a recently identified variant of NHL.
- Characterized by a specific morphology where over 30% of malignant cells exhibit multilobation.
Purpose of the Study:
- To characterize the immunologic phenotype, clinical presentation, and outcomes of patients with multilobated NHL.
- To determine if multilobated NHL represents a distinct clinicopathologic entity.
Main Methods:
- Retrospective analysis of 30 patients diagnosed with NHL over a 10-year period.
- Immunophenotypic analysis performed on 14 cases.
- Clinical follow-up data including remission rates, duration, and survival analyzed.
Main Results:
- Of 14 cases with immunophenotyping, one was T-cell lineage, and the rest were B-lymphoid.
- 68% of patients presented with extranodal disease.
- 78% achieved complete remission with a mean duration of 37 months; 5-year actuarial survival was 45%.
Conclusions:
- Multilobated NHL shares similarities with intermediate-grade lymphomas (Working Formulation, Kiel classification).
- Neoplastic cells are considered variants of follicle center cells.
- Clinicopathologic correlation supports multilobated NHL as a distinct nosologic entity.